A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients.
Brattström
C
C
Department of Transplantation Surgery, Huddinge Hospital, Sweden.
Tydén
G
G
Säwe
J
J
Herlenius
G
G
Claesson
K
K
Groth
C G
CG
D000328:Adult; D000368:Aged; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011090:Polyenes / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D011239:Prednisolone / Q000627:therapeutic use; D020123:Sirolimus
D007166:Immunosuppressive Agents; D010919:Placebos; D011090:Polyenes; D016572:Cyclosporine; D011239:Prednisolone; D001379:Azathioprine; D020123:Sirolimus